About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 419176, 9 pages
http://dx.doi.org/10.1155/2013/419176
Review Article

Progress of Molecular Targeted Therapies for Advanced Renal Cell Carcinoma

1Department of Clinical and Specialist Sciences, Urology, Polytechnic University of the Marche Region, AOU Ospedali Riuniti Umberto I-GM Lancisi and G Salesi, Ancona, Italy
2Medical Oncology, Polytechnic University of the Marche Region, AOU Ospedali Riuniti Umberto I-GM Lancisi and G Salesi, Ancona, Italy
3School of Pharmacy, Section of Experimental Medicine, University of Camerino, Italy

Received 30 April 2013; Revised 13 July 2013; Accepted 3 August 2013

Academic Editor: Jeanny B. Aragon-Ching

Copyright © 2013 Alessandro Conti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Zimmer, D. Doucette, N. Siddiqui, and O. Iliopoulos, “Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL/ tumors,” Molecular Cancer Research, vol. 2, no. 2, pp. 89–95, 2004. View at Scopus
  2. B. I. Rini and E. J. Small, “Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma,” Journal of Clinical Oncology, vol. 23, no. 5, pp. 1028–1043, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. G. L. Semenza, “Targeting HIF-1 for cancer therapy,” Nature Reviews Cancer, vol. 3, no. 10, pp. 721–732, 2003. View at Scopus
  4. K. Podar and K. C. Anderson, “A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways,” Cell Cycle, vol. 9, no. 9, pp. 1722–1728, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Holash, P. C. Maisonpierre, D. Compton et al., “Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF,” Science, vol. 284, no. 5422, pp. 1994–1998, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. B. Hemmerlein, A. Kugler, R. Özisik, R.-H. Ringert, H.-J. Radzun, and P. Thelen, “Vascular endothelial growth factor expression, angiogenesis, and necrosis in renal cell carcinomas,” Virchows Archiv, vol. 439, no. 5, pp. 645–652, 2001. View at Scopus
  7. N. Tsuchiya, K. Sato, T. Akao et al., “Quantitative analysis of gene expressions of vascular endothelial growth factor-related factors and their receptors in renal cell carcinoma,” Tohoku Journal of Experimental Medicine, vol. 195, no. 2, pp. 101–113, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Bergers and L. E. Benjamin, “Tumorigenesis and the angiogenic switch,” Nature Reviews Cancer, vol. 3, no. 6, pp. 401–410, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. X. Na, G. Wu, C. K. Ryan, S. R. Schoen, P. A. Di'Santagnese, and E. M. Messing, “Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1α expression in renal cell carcinomas,” Journal of Urology, vol. 170, no. 2 I, pp. 588–592, 2003. View at Scopus
  10. N. S. Levy, S. Chung, H. Furneaux, and A. P. Levy, “Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR,” The Journal of Biological Chemistry, vol. 273, no. 11, pp. 6417–6423, 1998. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Vroling, A. A. M. Van Der Veldt, R. R. De Haas et al., “Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib,” Angiogenesis, vol. 12, no. 1, pp. 69–79, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. S. M. Bauer, R. J. Bauer, and O. C. Velazquez, “Angiogenesis, vasculogenesis, and induction of healing in chronic wounds,” Vascular and Endovascular Surgery, vol. 39, no. 4, pp. 293–306, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Bompais, J. Chagraoui, X. Canron et al., “Human endothelial cells derived from circulating progenitors display specific functional properties compared with mature vessel wall endothelial cells,” Blood, vol. 103, no. 7, pp. 2577–2584, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Bruno, B. Bussolati, C. Grange et al., “CD133+ renal progenitor cells contribute to tumor angiogenesis,” American Journal of Pathology, vol. 169, no. 6, pp. 2223–2235, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Rafii, S. Avecilla, S. Shmelkov et al., “Angiogenic factors reconstitute hematopoiesis by recruiting stem cells from bone marrow microenvironment,” Annals of the New York Academy of Sciences, vol. 996, pp. 49–60, 2003. View at Scopus
  16. D. J. Ceradini, A. R. Kulkarni, M. J. Callaghan et al., “Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1,” Nature Medicine, vol. 10, no. 8, pp. 858–864, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. R. N. Kaplan, R. D. Riba, S. Zacharoulis et al., “VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche,” Nature, vol. 438, no. 7069, pp. 820–827, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Powles, S. Chowdhury, J. Shamash et al., “Increased haematopoietic progenitor cells are associated with poor outcome in patients with metastatic renal cancer treated with sunitinib,” Annals of Oncology, vol. 22, no. 4, pp. 815–820, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. L. H. Parker, M. Schmidt, S.-W. Jin et al., “The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation,” Nature, vol. 428, no. 6984, pp. 754–758, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Betsholtz, P. Lindblom, and H. Gerhardt, “Role of pericytes in vascular morphogenesis,” EXS, no. 94, pp. 115–125, 2005. View at Scopus
  21. V. A. Carroll and M. Ashcroft, “Regulation of angiogenic factors by HDM2 in renal cell carcinoma,” Cancer Research, vol. 68, no. 2, pp. 545–552, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Santoni, M. Rizzo, L. Burattini, R. Berardi, G. Carteni, and S. Cascinu, “Novel agents, combinations and sequences for the treatment of advanced renal cell carcinoma: when is the revolution coming?” Current Cancer Drug Targets, vol. 13, no. 3, pp. 313–325, 2013. View at Publisher · View at Google Scholar
  23. B. I. Rini, G. Wilding, G. Hudes et al., “Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma,” Journal of Clinical Oncology, vol. 27, no. 27, pp. 4462–4468, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. O. Rixe, R. M. Bukowski, M. D. Michaelson et al., “Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study,” Lancet Oncology, vol. 8, no. 11, pp. 975–984, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. B. I. Rini, B. Escudier, P. Tomczak et al., “Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial,” The Lancet, vol. 378, no. 9807, pp. 1931–1939, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. B. I. Rini, V. Grünwald, M. N. Fishman, et al., “Axitinib for first-line metastatic renal cell carcinoma (mRCC): overall efficacy and pharmacokinetic analyses from a randomized phase II study,” Journal of Clinical Oncology. In press.
  27. P. Bhargava, B. Esteves, D. A. Nosov, O. N. Lipatov, A. A. Lyulko, A. A. Anischenko, et al., “Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC),” Journal of Clinical Oncology. In press.
  28. R. J. Motzer, D. Nosov, T. Eisen, I. N. Bondarenko, V. Lesovoy, O. N. Lipatov, et al., “Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: results from a phase III randomized,” Journal of Clinical Oncology. In press.
  29. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Oncologic DrugsAdvisoryCommittee/UCM350075.pdf.
  30. E. Angevin, V. Grünwald, A. Ravaud, D. E. Castellano, C. C. Lin, J. E. Gschwend, et al., “A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC),” Journal of Clinical Oncology. In press.
  31. J. C. Welti, M. Gourlaouen, T. Powles et al., “Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib,” Oncogene, vol. 30, no. 10, pp. 1183–1193, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. P. Mulders, R. Hawkins, P. Nathan et al., “Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study,” European Journal of Cancer, vol. 48, no. 4, pp. 527–537, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. N. M. Tannir, Y.-N. Wong, C. K. Kollmannsberger et al., “Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure,” European Journal of Cancer, vol. 47, no. 18, pp. 2706–2714, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Eisen, H. Joensuu, P. D. Nathan, P. G. Harper, M. Z. Wojtukiewicz, S. Nicholson, et al., “Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma:a single-group phase 2 trial,” The Lancet Oncology, vol. 13, no. 10, pp. 1055–1062, 2012. View at Publisher · View at Google Scholar
  35. M. Jermann, R. A. Stahel, M. Salzberg et al., “A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma,” Cancer Chemotherapy and Pharmacology, vol. 57, no. 4, pp. 533–539, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. D. Shek, J. Longmate, D. I. Quinn et al., “A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma,” International Journal of Clinical Oncology, vol. 16, no. 5, pp. 494–499, 2011. View at Scopus
  37. D. R. Shepard, M. M. Cooney, P. Elson et al., “A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma,” Investigational New Drugs, vol. 30, no. 1, pp. 364–367, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. H. M. W. Verheul, H. Hammers, K. Van Erp et al., “Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model,” Clinical Cancer Research, vol. 13, no. 14, pp. 4201–4208, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. W. P. Tew, M. Gordon, J. Murren et al., “Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors,” Clinical Cancer Research, vol. 16, no. 1, pp. 358–366, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Mita, E. Rowinsky, A. Mita, S. Syed, Q. Chu, M. Goldston, et al., “Phase 1, pharmacokinetic (PK), and pharmacodynamic (PD) study of AP23573, an mTOR Inhibitor, administered IV daily X 5 every other week in patients (patients) with refractory or advanced malignancies,” Journal of Clinical Oncology, vol. 22, no. 14, p. 3076, 2004.
  41. C. M. Chresta, B. R. Davies, I. Hickson et al., “AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity,” Cancer Research, vol. 70, no. 1, pp. 288–298, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. D. C. Cho, T. E. Hutson, W. Samlowski, P. Sportelli, B. Somer, P. Richards, et al., “Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy,” Cancer, vol. 118, pp. 6055–6062, 2012. View at Publisher · View at Google Scholar
  43. D. C. Cho, M. B. Cohen, D. J. Panka et al., “The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma,” Clinical Cancer Research, vol. 16, no. 14, pp. 3628–3638, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. D. Roulin, L. Waselle, A. Dormond-Meuwly, M. Dufour, N. Demartines, and O. Dormond, “Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib,” Molecular Cancer, vol. 10, article 90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. B. Rini, C. Szczylik, N. M. Tannir, P. Koralewski, P. Tomczak, A. Deptala, et al., “AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study,” Cancer, vol. 118, pp. 6152–6161, 2012. View at Publisher · View at Google Scholar
  46. M. B. Atkins, A. Ravaud, G. Gravis, K. Drosik, T. Demkow, P. Tomczak, et al., “Safety and efficacy of AMG 386 in combination with sunitinib in patients with metastatic renal cell carcinoma (mRCC) in an open-label multicenter phase II study,” Journal of Clinical Oncology. In press.
  47. V. Ramakrishnan, V. Bhaskar, D. A. Law et al., “Preclinical evaluation of an anti-α5β1 integrin antibody as a novel anti-angiogenic agent,” Journal of Experimental Therapeutics and Oncology, vol. 5, no. 4, pp. 273–286, 2006. View at Scopus
  48. S. Yazji, R. M. Bukowksi, V. Kondagunta, and R. Figlin, “Final results from phase II study of volociximab, an a5B1 anti-integrin antibody, in refractory or relapsed metastatic clear cell renal cell carcinoma (mCCRCC),” Journal of Clinical Oncology. In press.
  49. C.-L. Law, K. A. Gordon, B. E. Toki et al., “Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates,” Cancer Research, vol. 66, no. 4, pp. 2328–2337, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. E. Oosterwijk, D. J. Ruiter, and J. Hoedemaeker Ph., “Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney,” International Journal of Cancer, vol. 38, no. 4, pp. 489–494, 1986. View at Scopus
  51. Z. Liu, F. E. Smyth, C. Renner, F.-T. Lee, E. Oosterwijk, and A. M. Scott, “Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity,” Cancer Immunology, Immunotherapy, vol. 51, no. 3, pp. 171–177, 2002. View at Publisher · View at Google Scholar · View at Scopus
  52. Y. Shao, Z. Gao, P. A. Marks, and X. Jiang, “Apoptotic and autophagic cell death induced by histone deacetylase inhibitors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 52, pp. 18030–18035, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. P. Rocchi, R. Tonelli, C. Camerin et al., “p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells,” Oncology Reports, vol. 13, no. 6, pp. 1139–1144, 2005. View at Scopus
  54. H. Wang, W. Zhou, Z. Zheng et al., “The HDAC inhibitor depsipeptide transactivates the p53/p21 pathway by inducing DNA damage,” DNA Repair, vol. 11, no. 2, pp. 146–156, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. J. D. Hainsworth, J. R. Infante, D. R. Spigel, E. R. Arrowsmith, R. V. Boccia, and H. A. Burris, “A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma,” Cancer Investigation, vol. 29, no. 7, pp. 451–455, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. G. Niu, K. L. Wright, M. Huang et al., “Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis,” Oncogene, vol. 21, no. 13, pp. 2000–2008, 2002. View at Publisher · View at Google Scholar · View at Scopus
  57. A. Horiguchi, T. Asano, K. Kuroda et al., “STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma,” British Journal of Cancer, vol. 102, no. 11, pp. 1592–1599, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. C. R. Ireson and L. R. Kelland, “Discovery and development of anticancer aptamers,” Molecular Cancer Therapeutics, vol. 5, no. 12, pp. 2957–2962, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. H. Ginisty, H. Sicard, B. Roger, and P. Bouvet, “Structure and functions of nucleolin,” Journal of Cell Science, vol. 112, no. 6, pp. 761–772, 1999. View at Scopus
  60. S. Soundararajan, W. Chen, E. K. Spicer, N. Courtenay-Luck, and D. J. Fernandes, “The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells,” Cancer Research, vol. 68, no. 7, pp. 2358–2365, 2008. View at Publisher · View at Google Scholar · View at Scopus